Researchers published the most comprehensive data to date showing that Grail's screening approach can detect and distinguish a significant number of cancers.
The firm believes that its molecular assay for the laboratory will help ease some of the supply chain issues hampering test rollout during the pandemic.
The assay, which resembles a pregnancy test, is authorized for use in laboratories certified under CLIA to perform as moderate- and highly-complexity tests.
